APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Inflammatory Bowel Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Inflammatory Bowel Disease Drugs Industry Research Report 2026

22 December 2025130 pages

Choose your research edition.

Industry ResearchInflammatory Bowel Disease Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Inflammatory Bowel Disease Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Inflammatory Bowel Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Inflammatory Bowel Disease Drugs Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Inflammatory Bowel Disease Drugs Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Inflammatory Bowel Disease Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Inflammatory Bowel Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Inflammatory Bowel Disease Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Inflammatory Bowel Disease Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Inflammatory Bowel Disease Drugs include Takeda Pharmaceutical, Sanofi, Johnson and Johnson, Novartis AG, Mylan Pharmaceuticals, Roche, Pfizer, AbbVie Inc and UCB S.A., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Inflammatory Bowel Disease Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Inflammatory Bowel Disease Drugs Market by Company

Takeda Pharmaceutical

Sanofi

Johnson and Johnson

Novartis AG

Mylan Pharmaceuticals

Roche

Pfizer

AbbVie Inc

UCB S.A.

Quest Medical

Merck & Co, Inc

Eli-Lilly

Celltrion Healthcare

Bristol Myers Squibb

Biocon Ltd

Abbott Laboratories

Inflammatory Bowel Disease Drugs Segment by Type

Biologics

Corticosteroids

Immunomodulators

Antibiotics

Amino-salicylates

Others

Inflammatory Bowel Disease Drugs Segment by Application

Indeterminate Colitis

Ulcerative Colitis

Crohns Disease

Others

Inflammatory Bowel Disease Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inflammatory Bowel Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Inflammatory Bowel Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inflammatory Bowel Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Inflammatory Bowel Disease Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Inflammatory Bowel Disease Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Inflammatory Bowel Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Inflammatory Bowel Disease Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Inflammatory Bowel Disease Drugs Sales (k units) of Manufacturers (2021-2026) Table 7. Global Inflammatory Bowel Disease Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Inflammatory Bowel Disease Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Inflammatory Bowel Disease Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Inflammatory Bowel Disease Drugs Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Inflammatory Bowel Disease Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Inflammatory Bowel Disease Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Inflammatory Bowel Disease Drugs, Product Type & Application Table 14. Global Inflammatory Bowel Disease Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Inflammatory Bowel Disease Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Takeda Pharmaceutical Company Information Table 19. Takeda Pharmaceutical Business Overview Table 20. Takeda Pharmaceutical Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Takeda Pharmaceutical Inflammatory Bowel Disease Drugs Product Portfolio Table 22. Takeda Pharmaceutical Recent Developments Table 23. Sanofi Company Information Table 24. Sanofi Business Overview Table 25. Sanofi Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Sanofi Inflammatory Bowel Disease Drugs Product Portfolio Table 27. Sanofi Recent Developments Table 28. Johnson and Johnson Company Information Table 29. Johnson and Johnson Business Overview Table 30. Johnson and Johnson Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Johnson and Johnson Inflammatory Bowel Disease Drugs Product Portfolio Table 32. Johnson and Johnson Recent Developments Table 33. Novartis AG Company Information Table 34. Novartis AG Business Overview Table 35. Novartis AG Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Novartis AG Inflammatory Bowel Disease Drugs Product Portfolio Table 37. Novartis AG Recent Developments Table 38. Mylan Pharmaceuticals Company Information Table 39. Mylan Pharmaceuticals Business Overview Table 40. Mylan Pharmaceuticals Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Mylan Pharmaceuticals Inflammatory Bowel Disease Drugs Product Portfolio Table 42. Mylan Pharmaceuticals Recent Developments Table 43. Roche Company Information Table 44. Roche Business Overview Table 45. Roche Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Roche Inflammatory Bowel Disease Drugs Product Portfolio Table 47. Roche Recent Developments Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Pfizer Inflammatory Bowel Disease Drugs Product Portfolio Table 52. Pfizer Recent Developments Table 53. AbbVie Inc Company Information Table 54. AbbVie Inc Business Overview Table 55. AbbVie Inc Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. AbbVie Inc Inflammatory Bowel Disease Drugs Product Portfolio Table 57. AbbVie Inc Recent Developments Table 58. UCB S.A. Company Information Table 59. UCB S.A. Business Overview Table 60. UCB S.A. Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. UCB S.A. Inflammatory Bowel Disease Drugs Product Portfolio Table 62. UCB S.A. Recent Developments Table 63. Quest Medical Company Information Table 64. Quest Medical Business Overview Table 65. Quest Medical Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Quest Medical Inflammatory Bowel Disease Drugs Product Portfolio Table 67. Quest Medical Recent Developments Table 68. Merck & Co, Inc Company Information Table 69. Merck & Co, Inc Business Overview Table 70. Merck & Co, Inc Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Merck & Co, Inc Inflammatory Bowel Disease Drugs Product Portfolio Table 72. Merck & Co, Inc Recent Developments Table 73. Eli-Lilly Company Information Table 74. Eli-Lilly Business Overview Table 75. Eli-Lilly Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Eli-Lilly Inflammatory Bowel Disease Drugs Product Portfolio Table 77. Eli-Lilly Recent Developments Table 78. Celltrion Healthcare Company Information Table 79. Celltrion Healthcare Business Overview Table 80. Celltrion Healthcare Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Celltrion Healthcare Inflammatory Bowel Disease Drugs Product Portfolio Table 82. Celltrion Healthcare Recent Developments Table 83. Bristol Myers Squibb Company Information Table 84. Bristol Myers Squibb Business Overview Table 85. Bristol Myers Squibb Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Bristol Myers Squibb Inflammatory Bowel Disease Drugs Product Portfolio Table 87. Bristol Myers Squibb Recent Developments Table 88. Biocon Ltd Company Information Table 89. Biocon Ltd Business Overview Table 90. Biocon Ltd Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Biocon Ltd Inflammatory Bowel Disease Drugs Product Portfolio Table 92. Biocon Ltd Recent Developments Table 93. Abbott Laboratories Company Information Table 94. Abbott Laboratories Business Overview Table 95. Abbott Laboratories Inflammatory Bowel Disease Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Abbott Laboratories Inflammatory Bowel Disease Drugs Product Portfolio Table 97. Abbott Laboratories Recent Developments Table 98. Global Inflammatory Bowel Disease Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 99. Global Inflammatory Bowel Disease Drugs Sales by Region (2021-2026) & (k units) Table 100. Global Inflammatory Bowel Disease Drugs Sales Market Share by Region (2021-2026) Table 101. Global Inflammatory Bowel Disease Drugs Sales by Region (2027-2032) & (k units) Table 102. Global Inflammatory Bowel Disease Drugs Sales Market Share by Region (2027-2032) Table 103. Global Inflammatory Bowel Disease Drugs Revenue by Region (2021-2026) & (US$ Million) Table 104. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Region (2021-2026) Table 105. Global Inflammatory Bowel Disease Drugs Revenue by Region (2027-2032) & (US$ Million) Table 106. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Region (2027-2032) Table 107. North America Inflammatory Bowel Disease Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. North America Inflammatory Bowel Disease Drugs Sales by Country (2021-2026) & (k units) Table 109. North America Inflammatory Bowel Disease Drugs Sales by Country (2027-2032) & (k units) Table 110. North America Inflammatory Bowel Disease Drugs Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Inflammatory Bowel Disease Drugs Revenue by Country (2027-2032) & (US$ Million) Table 112. Europe Inflammatory Bowel Disease Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Europe Inflammatory Bowel Disease Drugs Sales by Country (2021-2026) & (k units) Table 114. Europe Inflammatory Bowel Disease Drugs Sales by Country (2027-2032) & (k units) Table 115. Europe Inflammatory Bowel Disease Drugs Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Inflammatory Bowel Disease Drugs Revenue by Country (2027-2032) & (US$ Million) Table 117. Asia Pacific Inflammatory Bowel Disease Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Asia Pacific Inflammatory Bowel Disease Drugs Sales by Country (2021-2026) & (k units) Table 119. Asia Pacific Inflammatory Bowel Disease Drugs Sales by Country (2027-2032) & (k units) Table 120. Asia Pacific Inflammatory Bowel Disease Drugs Revenue by Country (2021-2026) & (US$ Million) Table 121. Asia Pacific Inflammatory Bowel Disease Drugs Revenue by Country (2027-2032) & (US$ Million) Table 122. South America Inflammatory Bowel Disease Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. South America Inflammatory Bowel Disease Drugs Sales by Country (2021-2026) & (k units) Table 124. South America Inflammatory Bowel Disease Drugs Sales by Country (2027-2032) & (k units) Table 125. South America Inflammatory Bowel Disease Drugs Revenue by Country (2021-2026) & (US$ Million) Table 126. South America Inflammatory Bowel Disease Drugs Revenue by Country (2027-2032) & (US$ Million) Table 127. Middle East and Africa Inflammatory Bowel Disease Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Middle East and Africa Inflammatory Bowel Disease Drugs Sales by Country (2021-2026) & (k units) Table 129. Middle East and Africa Inflammatory Bowel Disease Drugs Sales by Country (2027-2032) & (k units) Table 130. Middle East and Africa Inflammatory Bowel Disease Drugs Revenue by Country (2021-2026) & (US$ Million) Table 131. Middle East and Africa Inflammatory Bowel Disease Drugs Revenue by Country (2027-2032) & (US$ Million) Table 132. Global Inflammatory Bowel Disease Drugs Sales by Type (2021-2026) & (k units) Table 133. Global Inflammatory Bowel Disease Drugs Sales by Type (2027-2032) & (k units) Table 134. Global Inflammatory Bowel Disease Drugs Sales Market Share by Type (2021-2026) Table 135. Global Inflammatory Bowel Disease Drugs Sales Market Share by Type (2027-2032) Table 136. Global Inflammatory Bowel Disease Drugs Revenue by Type (2021-2026) & (US$ Million) Table 137. Global Inflammatory Bowel Disease Drugs Revenue by Type (2027-2032) & (US$ Million) Table 138. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Type (2021-2026) Table 139. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Type (2027-2032) Table 140. Global Inflammatory Bowel Disease Drugs Price by Type (2021-2026) & (US$/unit) Table 141. Global Inflammatory Bowel Disease Drugs Price by Type (2027-2032) & (US$/unit) Table 142. Global Inflammatory Bowel Disease Drugs Sales by Application (2021-2026) & (k units) Table 143. Global Inflammatory Bowel Disease Drugs Sales by Application (2027-2032) & (k units) Table 144. Global Inflammatory Bowel Disease Drugs Sales Market Share by Application (2021-2026) Table 145. Global Inflammatory Bowel Disease Drugs Sales Market Share by Application (2027-2032) Table 146. Global Inflammatory Bowel Disease Drugs Revenue by Application (2021-2026) & (US$ Million) Table 147. Global Inflammatory Bowel Disease Drugs Revenue by Application (2027-2032) & (US$ Million) Table 148. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Application (2021-2026) Table 149. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Application (2027-2032) Table 150. Global Inflammatory Bowel Disease Drugs Price by Application (2021-2026) & (US$/unit) Table 151. Global Inflammatory Bowel Disease Drugs Price by Application (2027-2032) & (US$/unit) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Inflammatory Bowel Disease Drugs Distributors List Table 155. Inflammatory Bowel Disease Drugs Customers List Table 156. Inflammatory Bowel Disease Drugs Industry Trends Table 157. Inflammatory Bowel Disease Drugs Industry Drivers Table 158. Inflammatory Bowel Disease Drugs Industry Restraints Table 159. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Inflammatory Bowel Disease Drugs Product Image Figure 5. Global Inflammatory Bowel Disease Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Inflammatory Bowel Disease Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Inflammatory Bowel Disease Drugs Sales (2021-2032) & (k units) Figure 8. Global Inflammatory Bowel Disease Drugs Average Price (US$/unit) & (2021-2032) Figure 9. Biologics Product Image Figure 10. Corticosteroids Product Image Figure 11. Immunomodulators Product Image Figure 12. Antibiotics Product Image Figure 13. Amino-salicylates Product Image Figure 14. Others Product Image Figure 15. Indeterminate Colitis Product Image Figure 16. Ulcerative Colitis Product Image Figure 17. Crohns Disease Product Image Figure 18. Others Product Image Figure 19. Global Inflammatory Bowel Disease Drugs Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Inflammatory Bowel Disease Drugs, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Inflammatory Bowel Disease Drugs Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Inflammatory Bowel Disease Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Inflammatory Bowel Disease Drugs Sales by Region in 2025 Figure 25. Global Inflammatory Bowel Disease Drugs Revenue by Region in 2025 Figure 26. North America Inflammatory Bowel Disease Drugs Market Size by Country in 2025 Figure 27. North America Inflammatory Bowel Disease Drugs Sales Market Share by Country (2021-2032) Figure 28. North America Inflammatory Bowel Disease Drugs Revenue Market Share by Country (2021-2032) Figure 29. United States Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Mexico Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Europe Inflammatory Bowel Disease Drugs Market Size by Country in 2025 Figure 33. Europe Inflammatory Bowel Disease Drugs Sales Market Share by Country (2021-2032) Figure 34. Europe Inflammatory Bowel Disease Drugs Revenue Market Share by Country (2021-2032) Figure 35. Germany Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. France Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. U.K. Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Italy Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Russia Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Spain Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Netherlands Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Switzerland Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Sweden Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Poland Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Asia Pacific Inflammatory Bowel Disease Drugs Market Size by Country in 2025 Figure 46. Asia Pacific Inflammatory Bowel Disease Drugs Sales Market Share by Country (2021-2032) Figure 47. Asia Pacific Inflammatory Bowel Disease Drugs Revenue Market Share by Country (2021-2032) Figure 48. China Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Japan Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South Korea Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. India Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Australia Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Taiwan Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. South America Inflammatory Bowel Disease Drugs Market Size by Country in 2025 Figure 57. South America Inflammatory Bowel Disease Drugs Sales Market Share by Country (2021-2032) Figure 58. South America Inflammatory Bowel Disease Drugs Revenue Market Share by Country (2021-2032) Figure 59. Brazil Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Argentina Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Chile Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Middle East and Africa Inflammatory Bowel Disease Drugs Market Size by Country in 2025 Figure 63. Middle East and Africa Inflammatory Bowel Disease Drugs Sales Market Share by Country (2021-2032) Figure 64. Middle East and Africa Inflammatory Bowel Disease Drugs Revenue Market Share by Country (2021-2032) Figure 65. Egypt Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. South Africa Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Israel Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Türkiye Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. GCC Countries Inflammatory Bowel Disease Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Global Inflammatory Bowel Disease Drugs Sales Market Share by Type (2021-2032) Figure 71. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Type (2021-2032) Figure 72. Global Inflammatory Bowel Disease Drugs Price (US$/unit) by Type (2021-2032) Figure 73. Global Inflammatory Bowel Disease Drugs Sales Market Share by Application (2021-2032) Figure 74. Global Inflammatory Bowel Disease Drugs Revenue Market Share by Application (2021-2032) Figure 75. Global Inflammatory Bowel Disease Drugs Price (US$/unit) by Application (2021-2032) Figure 76. Inflammatory Bowel Disease Drugs Value Chain Figure 77. Inflammatory Bowel Disease Drugs Production Mode & Process Figure 78. Direct Comparison with Distribution Share Figure 79. Distributors Profiles Figure 80. Inflammatory Bowel Disease Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Biologics
  • Corticosteroids
  • Immunomodulators
  • Antibiotics
  • Amino-salicylates
  • Others
Applications
  • Indeterminate Colitis
  • Ulcerative Colitis
  • Crohns Disease
  • Others
Companies covered
  • Takeda Pharmaceutical
  • Sanofi
  • Johnson and Johnson
  • Novartis AG
  • Mylan Pharmaceuticals
  • Roche
  • Pfizer
  • AbbVie Inc
  • UCB S.A.
  • Quest Medical
  • Merck & Co, Inc
  • Eli-Lilly
  • Celltrion Healthcare
  • Bristol Myers Squibb
  • Biocon Ltd
  • Abbott Laboratories

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Inflammatory Bowel Disease Drugs Market Size (2021-2032)
  4. 2.2.2 Global Inflammatory Bowel Disease Drugs Sales (2021-2032)
  5. 2.2.3 Global Inflammatory Bowel Disease Drugs Market Average Price (2021-2032)
  6. 2.3 Inflammatory Bowel Disease Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Biologics
  9. 2.3.3 Corticosteroids
  10. 2.3.4 Immunomodulators
  11. 2.3.5 Antibiotics
  12. 2.3.6 Amino-salicylates
  13. 2.3.7 Others
  14. 2.4 Inflammatory Bowel Disease Drugs by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Indeterminate Colitis
  17. 2.4.3 Ulcerative Colitis
  18. 2.4.4 Crohns Disease
  19. 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Inflammatory Bowel Disease Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Inflammatory Bowel Disease Drugs Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Inflammatory Bowel Disease Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Inflammatory Bowel Disease Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Inflammatory Bowel Disease Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Inflammatory Bowel Disease Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Inflammatory Bowel Disease Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Inflammatory Bowel Disease Drugs, Established Date
  9. 3.9 Global Inflammatory Bowel Disease Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Takeda Pharmaceutical
  2. 4.1.1 Takeda Pharmaceutical Company Information
  3. 4.1.2 Takeda Pharmaceutical Business Overview
  4. 4.1.3 Takeda Pharmaceutical Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Takeda Pharmaceutical Inflammatory Bowel Disease Drugs Product Portfolio
  6. 4.1.5 Takeda Pharmaceutical Recent Developments
  7. 4.2 Sanofi
  8. 4.2.1 Sanofi Company Information
  9. 4.2.2 Sanofi Business Overview
  10. 4.2.3 Sanofi Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Sanofi Inflammatory Bowel Disease Drugs Product Portfolio
  12. 4.2.5 Sanofi Recent Developments
  13. 4.3 Johnson and Johnson
  14. 4.3.1 Johnson and Johnson Company Information
  15. 4.3.2 Johnson and Johnson Business Overview
  16. 4.3.3 Johnson and Johnson Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Johnson and Johnson Inflammatory Bowel Disease Drugs Product Portfolio
  18. 4.3.5 Johnson and Johnson Recent Developments
  19. 4.4 Novartis AG
  20. 4.4.1 Novartis AG Company Information
  21. 4.4.2 Novartis AG Business Overview
  22. 4.4.3 Novartis AG Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Novartis AG Inflammatory Bowel Disease Drugs Product Portfolio
  24. 4.4.5 Novartis AG Recent Developments
  25. 4.5 Mylan Pharmaceuticals
  26. 4.5.1 Mylan Pharmaceuticals Company Information
  27. 4.5.2 Mylan Pharmaceuticals Business Overview
  28. 4.5.3 Mylan Pharmaceuticals Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Mylan Pharmaceuticals Inflammatory Bowel Disease Drugs Product Portfolio
  30. 4.5.5 Mylan Pharmaceuticals Recent Developments
  31. 4.6 Roche
  32. 4.6.1 Roche Company Information
  33. 4.6.2 Roche Business Overview
  34. 4.6.3 Roche Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Roche Inflammatory Bowel Disease Drugs Product Portfolio
  36. 4.6.5 Roche Recent Developments
  37. 4.7 Pfizer
  38. 4.7.1 Pfizer Company Information
  39. 4.7.2 Pfizer Business Overview
  40. 4.7.3 Pfizer Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pfizer Inflammatory Bowel Disease Drugs Product Portfolio
  42. 4.7.5 Pfizer Recent Developments
  43. 4.8 AbbVie Inc
  44. 4.8.1 AbbVie Inc Company Information
  45. 4.8.2 AbbVie Inc Business Overview
  46. 4.8.3 AbbVie Inc Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 AbbVie Inc Inflammatory Bowel Disease Drugs Product Portfolio
  48. 4.8.5 AbbVie Inc Recent Developments
  49. 4.9 UCB S.A.
  50. 4.9.1 UCB S.A. Company Information
  51. 4.9.2 UCB S.A. Business Overview
  52. 4.9.3 UCB S.A. Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 UCB S.A. Inflammatory Bowel Disease Drugs Product Portfolio
  54. 4.9.5 UCB S.A. Recent Developments
  55. 4.10 Quest Medical
  56. 4.10.1 Quest Medical Company Information
  57. 4.10.2 Quest Medical Business Overview
  58. 4.10.3 Quest Medical Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Quest Medical Inflammatory Bowel Disease Drugs Product Portfolio
  60. 4.10.5 Quest Medical Recent Developments
  61. 4.11 Merck & Co, Inc
  62. 4.11.1 Merck & Co, Inc Company Information
  63. 4.11.2 Merck & Co, Inc Business Overview
  64. 4.11.3 Merck & Co, Inc Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Merck & Co, Inc Inflammatory Bowel Disease Drugs Product Portfolio
  66. 4.11.5 Merck & Co, Inc Recent Developments
  67. 4.12 Eli-Lilly
  68. 4.12.1 Eli-Lilly Company Information
  69. 4.12.2 Eli-Lilly Business Overview
  70. 4.12.3 Eli-Lilly Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Eli-Lilly Inflammatory Bowel Disease Drugs Product Portfolio
  72. 4.12.5 Eli-Lilly Recent Developments
  73. 4.13 Celltrion Healthcare
  74. 4.13.1 Celltrion Healthcare Company Information
  75. 4.13.2 Celltrion Healthcare Business Overview
  76. 4.13.3 Celltrion Healthcare Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Celltrion Healthcare Inflammatory Bowel Disease Drugs Product Portfolio
  78. 4.13.5 Celltrion Healthcare Recent Developments
  79. 4.14 Bristol Myers Squibb
  80. 4.14.1 Bristol Myers Squibb Company Information
  81. 4.14.2 Bristol Myers Squibb Business Overview
  82. 4.14.3 Bristol Myers Squibb Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Bristol Myers Squibb Inflammatory Bowel Disease Drugs Product Portfolio
  84. 4.14.5 Bristol Myers Squibb Recent Developments
  85. 4.15 Biocon Ltd
  86. 4.15.1 Biocon Ltd Company Information
  87. 4.15.2 Biocon Ltd Business Overview
  88. 4.15.3 Biocon Ltd Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Biocon Ltd Inflammatory Bowel Disease Drugs Product Portfolio
  90. 4.15.5 Biocon Ltd Recent Developments
  91. 4.16 Abbott Laboratories
  92. 4.16.1 Abbott Laboratories Company Information
  93. 4.16.2 Abbott Laboratories Business Overview
  94. 4.16.3 Abbott Laboratories Inflammatory Bowel Disease Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Abbott Laboratories Inflammatory Bowel Disease Drugs Product Portfolio
  96. 4.16.5 Abbott Laboratories Recent Developments
5 Global Inflammatory Bowel Disease Drugs Market Scenario by Region
  1. 5.1 Global Inflammatory Bowel Disease Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Inflammatory Bowel Disease Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Inflammatory Bowel Disease Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Inflammatory Bowel Disease Drugs Sales by Region: 2027-2032
  5. 5.3 Global Inflammatory Bowel Disease Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Inflammatory Bowel Disease Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Inflammatory Bowel Disease Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Inflammatory Bowel Disease Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Inflammatory Bowel Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Inflammatory Bowel Disease Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Inflammatory Bowel Disease Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Inflammatory Bowel Disease Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Inflammatory Bowel Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Inflammatory Bowel Disease Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Inflammatory Bowel Disease Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Inflammatory Bowel Disease Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Inflammatory Bowel Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Inflammatory Bowel Disease Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Inflammatory Bowel Disease Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Inflammatory Bowel Disease Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Inflammatory Bowel Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Inflammatory Bowel Disease Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Inflammatory Bowel Disease Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Inflammatory Bowel Disease Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Inflammatory Bowel Disease Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Inflammatory Bowel Disease Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Inflammatory Bowel Disease Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Inflammatory Bowel Disease Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Inflammatory Bowel Disease Drugs Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Inflammatory Bowel Disease Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Inflammatory Bowel Disease Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Inflammatory Bowel Disease Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Inflammatory Bowel Disease Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Inflammatory Bowel Disease Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Inflammatory Bowel Disease Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Inflammatory Bowel Disease Drugs Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Inflammatory Bowel Disease Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Inflammatory Bowel Disease Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Inflammatory Bowel Disease Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Inflammatory Bowel Disease Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Inflammatory Bowel Disease Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Inflammatory Bowel Disease Drugs Value Chain Analysis
  2. 8.1.1 Inflammatory Bowel Disease Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Inflammatory Bowel Disease Drugs Production Mode & Process
  5. 8.2 Inflammatory Bowel Disease Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Inflammatory Bowel Disease Drugs Distributors
  8. 8.2.3 Inflammatory Bowel Disease Drugs Customers
9 Global Inflammatory Bowel Disease Drugs Analyzing Market Dynamics
  1. 9.1 Inflammatory Bowel Disease Drugs Industry Trends
  2. 9.2 Inflammatory Bowel Disease Drugs Industry Drivers
  3. 9.3 Inflammatory Bowel Disease Drugs Industry Opportunities and Challenges
  4. 9.4 Inflammatory Bowel Disease Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst